TY - JOUR
T1 - Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach
T2 - The Euro Heart Survey on atrial fibrillation
AU - The Euro Heart Survey
AU - Lip, Gregory Y.H.
AU - Nieuwlaat, Robby
AU - Pisters, Ron
AU - Lane, Deirdre A.
AU - Crijns, Harry J.G.M.
AU - Andresen, Dieter
AU - Camm, A. John
AU - Davies, Wynn
AU - Capucci, Alessandro
AU - Le´vy, Samuel
AU - Breithardt, Gu¨nter
AU - Cobbe, Stuart
AU - Le Heuzey, Jean Yves
AU - Santini, Massimo
AU - Vardas, Panos
AU - Manini, Malika
AU - Bramley, Claire
AU - Laforest, Vale´rie
AU - Taylor, Charles
AU - Del Gaiso, Susan
AU - Huber, Kurt
AU - De Backer, Guy
AU - Sirakova, Vera
AU - Cerbak, Roman
AU - Thayssen, Per
AU - Lehto, Seppo
AU - Blanc, Jean Jacques
AU - Delahaye, Franc¸ois
AU - Kobulia, Bondo
AU - Zeymer, Uwe
AU - Cokkinos, Dennis
AU - Karlocai, Kristof
AU - Graham, Ian
AU - Shelley, Emer
AU - Behar, Shlomo
AU - Maggioni, Aldo
AU - Gonc¸alves, Lino
AU - Grabauskiene, Virginija
AU - Asmussen, Inger
AU - Deckers, Jaap
AU - Stepinska, Janina
AU - Mareev, Vyacheslav
AU - Vasiljevic, Zorana
AU - Riecansky, Igor
AU - Kenda, Miran F.
AU - Alonso, Angeles
AU - Lopez-Sendon, Jose´ Luis
AU - Rosengren, Annika
AU - Buser, Peter
AU - Katz, Amos
N1 - Funding Information:
Funding/Support: The Euro Heart Survey is funded by industry sponsors AstraZeneca, Sanofi-Aventis, and Eucomed, and by the Austrian Heart Foundation, Austrian Society of Cardiology, French Federation of Cardiology, Hellenic Cardiological Society, Netherlands Heart Foundation, Portuguese Society of Cardiology, Spanish Cardiac Society, Swedish Heart and Lung Foundation and individual centers.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. Results: Risk categorization differed widely between the different schemes compared. Patients classified as high risk ranged from 10.2% with the Framingham schema to 75.7% with the Birmingham 2009 schema. The classic CHADS 2 (Congestive heart failure, Hypertension, Age > 75, Diabetes, prior Stroke/transient ischemic attack) schema categorized the largest proportion (61.9%) into the intermediate-risk strata, whereas the Birmingham 2009 schema classified 15.1% into this category. The Birmingham 2009 schema classified only 9.2% as low risk, whereas the Framingham scheme categorized 48.3% as low risk. Calculated C-statistics suggested modest predictive value of all schema for TE. The Birmingham 2009 schema fared marginally better (C-statistic, 0.606) than CHADS 2 . However, those classified as low risk by the Birmingham 2009 and NICE schema were truly low risk with no TE events recorded, whereas TE events occurred in 1.4% of low-risk CHADS 2 subjects. When expressed as a scoring system, the Birmingham 2009 schema (CHA 2 DS 2 -VASc acronym) showed an increase in TE rate with increasing scores ( P value for trend = .003). Conclusion: Our novel, simple stroke risk stratification schema, based on a risk factor approach, provides some improvement in predictive value for TE over the CHADS 2 schema, with low event rates in low-risk subjects and the classification of only a small proportion of subjects into the intermediate-risk category. This schema could improve our approach to stroke risk stratification in patients with AF.
AB - Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. Results: Risk categorization differed widely between the different schemes compared. Patients classified as high risk ranged from 10.2% with the Framingham schema to 75.7% with the Birmingham 2009 schema. The classic CHADS 2 (Congestive heart failure, Hypertension, Age > 75, Diabetes, prior Stroke/transient ischemic attack) schema categorized the largest proportion (61.9%) into the intermediate-risk strata, whereas the Birmingham 2009 schema classified 15.1% into this category. The Birmingham 2009 schema classified only 9.2% as low risk, whereas the Framingham scheme categorized 48.3% as low risk. Calculated C-statistics suggested modest predictive value of all schema for TE. The Birmingham 2009 schema fared marginally better (C-statistic, 0.606) than CHADS 2 . However, those classified as low risk by the Birmingham 2009 and NICE schema were truly low risk with no TE events recorded, whereas TE events occurred in 1.4% of low-risk CHADS 2 subjects. When expressed as a scoring system, the Birmingham 2009 schema (CHA 2 DS 2 -VASc acronym) showed an increase in TE rate with increasing scores ( P value for trend = .003). Conclusion: Our novel, simple stroke risk stratification schema, based on a risk factor approach, provides some improvement in predictive value for TE over the CHADS 2 schema, with low event rates in low-risk subjects and the classification of only a small proportion of subjects into the intermediate-risk category. This schema could improve our approach to stroke risk stratification in patients with AF.
UR - http://www.scopus.com/inward/record.url?scp=76749163232&partnerID=8YFLogxK
U2 - 10.1378/chest.09-1584
DO - 10.1378/chest.09-1584
M3 - Article
AN - SCOPUS:76749163232
SN - 0012-3692
VL - 137
SP - 263
EP - 272
JO - Chest
JF - Chest
IS - 2
ER -